NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Pilot Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Institute of Allergy and Infectious Diseases (NIAID)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 4 Years
Max Age: 65 Years

Referral Letter Required


Population Exclusion(s)

Pregnant Women


Monoclonal Antibody

Recruitment Keyword(s)



Chronic Granulomatous Disease;

Investigational Drug(s)


Investigational Device(s)



Biological/Vaccine: JSP191

Supporting Site

National Institute of Allergy and Infectious Diseases


Chronic granulomatous disease (CGD) is a rare immune disorder that can cause serious infections throughout the body. The only cure for CGD is a stem cell transplant. Transplants from a sibling are best, but many people must get transplants from unrelated donors. However, these transplants can cause serious complications in people with CGD.


To see if a study drug (JSP191) can help improve the success rates of stem cell transplants for people with CGD from an unrelated donor.


People aged 4 to 65 years with CGD who require a transplant.


Participants will be screened. Part of the screening will help to identify the best match to a transplant donor. Participants will have a physical exam, including dental and eye exams. They will have blood and urine tests. They will have tests of their breathing and heart function. A bone marrow sample will be taken. They will have their stem cells collected.

Participants will have a catheter inserted into a vein in their chest. It will remain in place for the entire period of transplant and recovery.

Participants will be in the hospital 40 to 50 days for the transplant. This will include a conditioning phase, to prepare their body for the procedure, as well as the transplant and recovery phases. As part of the conditioning phase, participants will receive JSP191 through a vein for 1 hour.

After discharge, participants will have follow-up visits 2 times a week for 100 days. Additional follow-up visits will continue for 5 years.

--Back to Top--



-Has confirmed CGD.

-Has sufficient complications from underlying disease to warrant undergoing transplantation (either a history of or ongoing inflammation/CGD-related autoimmunity OR a CGD-related infection while on prophylaxis) OR has a Quartile 1 or 2 residual oxidase production level.

-Aged 4 years to 65 years.

-Has an unrelated matched donor available (but no matched related donor available).

-Must be able to stay within 1 hours travel of the NIH for the first 3 months after transplantation and have a family member or other designated companion to stay with during the post-transplant period.

-Must provide a durable power of attorney for health care decisions to an appropriate adult relative or guardian in accordance with form NIH 200 NIH Durable Power of Attorney for Health Care Decision Making.

-If of childbearing potential, must agree to consistently use contraception from 1 month prior to baseline, throughout study participation, and for 1 year after receiving transplanted cells. Acceptable forms of contraception are:

--Contraceptive pills or patch, Norplant, Depo-Provera, or other FDA-approved contraceptive method.

--Male partner has previously undergone a vasectomy.

-If able to impregnate a partner, must agree to consistently use contraception from the time of enrollment through 3 months post-transplant. Acceptable forms of contraception are:

--Male condom with spermicide.


-Eastern Cooperative Oncology Group (ECOG) or equivalent performance status >= 3 (see Supportive Care guidelines, available at

-Left ventricular ejection fraction < 40%.

-Transaminases > 5x upper limit of normal based on the individual s clinical situation and at the discretion of the investigator.

-CRP > 100 mg/dL within 6 weeks of the transplant.

-Psychiatric disorder or mental deficiency severe enough as to make compliance with the HSCT unlikely, and/or to make regulatorily and legally effective informed consent impossible.

-Major anticipated illness or organ failure incompatible with survival from allogeneic HSCT.

-Pregnant or breastfeeding.

-HIV positive.

-Uncontrolled seizure disorder.

-Any condition or circumstance that the PI feels would create difficulty in maintaining compliance with the requirements of this protocol.

-Individuals who are not willing to submit their information as part of the alemtuzumab (Campath) Distribution Program application or participants whom the Distribution Program committee has determined are not qualified to receive alemtuzumab.

NOTE: Alemtuzumab (IV formulation) is no longer distributed commercially. In order to receive product, the physician must contact the program for the patient. If the patient is not willing to consent to submit their information (demographics, contact information, and rationale for use) to the program such that we can obtain the drug, then we cannot proceed with conditioning; therefore, the individual will not be eligible for this protocol.

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Elizabeth M. Kang, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
NIHBC 10 - CRC BG RM 6-3750
(301) 402-7567

Sandra Anaya-O'Brien, R.N.
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
Building 10
Room 5-3732
10 Center Drive
Bethesda, Maryland 20892
(301) 346-9781

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: TTY Users Dial 7-1-1

Clinical Trials Number:


--Back to Top--